Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.

Abstract:

PURPOSE:The methods (IHC/FISH) typically used to assess ER, PR, HER2, and Ki67 in FFPE specimens from breast cancer patients are difficult to set up, perform, and standardize for use in low and middle-income countries. Use of an automated diagnostic platform (GeneXpert®) and assay (Xpert® Breast Cancer STRAT4) that employs RT-qPCR to quantitate ESR1, PGR, ERBB2, and MKi67 mRNAs from formalin-fixed, paraffin-embedded (FFPE) tissues facilitates analyses in less than 3 h. This study compares breast cancer biomarker analyses using an RT-qPCR-based platform with analyses using standard IHC and FISH for assessment of the same biomarkers. METHODS:FFPE tissue sections from 523 patients were sent to a College of American Pathologists-certified central reference laboratory to evaluate concordance between IHC/FISH and STRAT4 using the laboratory's standard of care methods. A subset of 155 FFPE specimens was tested for concordance with STRAT4 using different IHC antibodies and scoring methods. RESULTS:Concordance between STRAT4 and IHC was 97.8% for ESR1, 90.4% for PGR, 93.3% for ERBB2 (IHC/FISH for HER2), and 78.6% for MKi67. Receiver operating characteristic curve (ROC) area under the curve (AUC) values of 0.99, 0.95, 0.99, and 0.85 were generated for ESR1, PGR, ERBB2, and MKi67, respectively. Minor variabilities were observed depending on the IHC antibody comparator used. CONCLUSION:Evaluation of breast cancer biomarker status by STRAT4 was highly concordant with central IHC/FISH in this blinded, retrospectively analyzed collection of samples. STRAT4 may provide a means to cost-effectively generate standardized diagnostic results for breast cancer patients in low- and middle-income countries.

authors

Wu NC,Wong W,Ho KE,Chu VC,Rizo A,Davenport S,Kelly D,Makar R,Jassem J,Duchnowska R,Biernat W,Radecka B,Fujita T,Klein JL,Stonecypher M,Ohta S,Juhl H,Weidler JM,Bates M,Press MF

doi

10.1007/s10549-018-4889-5

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

327-338

issue

2

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-4889-5

journal_volume

172

pub_type

杂志文章
  • Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

    abstract:BACKGROUND:We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor 'dimensions' were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying g...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05097-5

    authors: Camp NJ,Madsen MJ,Herranz J,Rodríguez-Lescure Á,Ruiz A,Martín M,Bernard PS

    更新日期:2019-05-01 00:00:00

  • Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls.

    abstract::Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. System...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-009-0650-4

    authors: Mao C,Wang XW,Qiu LX,Liao RY,Ding H,Chen Q

    更新日期:2010-06-01 00:00:00

  • False-negative rate of combined mammography and ultrasound for women with palpable breast masses.

    abstract::Mammography and ultrasound are often used concurrently for patients with palpable breast masses. While mammography has a false-negative rate of approximately 15 %, the addition of breast ultrasound decreases this rate among patients with palpable breast masses. There are no recent outcome data regarding the use of com...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3557-2

    authors: Chan CH,Coopey SB,Freer PE,Hughes KS

    更新日期:2015-10-01 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract:BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4115-x

    authors: Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期:2017-04-01 00:00:00

  • Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

    abstract::Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a conc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0715-4

    authors: Burks SR,Macedo LF,Barth ED,Tkaczuk KH,Martin SS,Rosen GM,Halpern HJ,Brodie AM,Kao JP

    更新日期:2010-11-01 00:00:00

  • Femara and the future: tailoring treatment and combination therapies with Femara.

    abstract::Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular pathways, resulting in the re-emergence of the disease. This is a distressing scenario for oncologists and patients, but recent intensive molecular and biochemical studies are beginning to unr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-007-9697-2

    authors: Ellis M,Ma C

    更新日期:2007-01-01 00:00:00

  • The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

    abstract:BACKGROUND:Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources. ME...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9679-4

    authors: Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

    更新日期:2008-06-01 00:00:00

  • Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

    abstract::Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period cha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0615-7

    authors: Lambe M,Wigertz A,Holmqvist M,Adolfsson J,Bardage C,Fornander T,Karlsson P,Odlind V,Persson I,Ahlgren J,Bergkvist L

    更新日期:2010-06-01 00:00:00

  • Frequent activation of CArG binding factor-A expression and binding in N-methyl-N-nitrosourea-induced rat mammary carcinomas.

    abstract::We previously identified a positive transcriptional element identical to human Ha-ras response element (HRE) within the promoter of the rat Ha-ras gene. We further identified CArG binding factor A (CBF-A), a member of heterogeneous nuclear ribonuclear protein (hnRNP) gene family, as a trans-acting factor that binds th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-1280-5

    authors: Mikheev AM,Inoue A,Jing L,Mikheeva SA,Li V,Leanderson T,Zarbl H

    更新日期:2004-11-01 00:00:00

  • Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

    abstract::The mitochondrial DNA (mtDNA) 4977-bp deletion (DeltamtDNA(4977) mutation) is one of the most frequently observed mtDNA mutations in human tissues and may play a role in carcinogenesis. Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9613-9

    authors: Ye C,Shu XO,Wen W,Pierce L,Courtney R,Gao YT,Zheng W,Cai Q

    更新日期:2008-04-01 00:00:00

  • Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.

    abstract::We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3672-0

    authors: Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

    更新日期:2016-01-01 00:00:00

  • Occult breast carcinoma in breast reduction specimens in European women.

    abstract::Breast reduction is a common surgical procedure performed by plastic and oncoplastic breast surgeons. The authors report on the incidence and management of cancer and atypical hyperplasia in breast reduction specimens from one institution over a 10-year period. All patients who underwent breast reduction surgery at No...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1589-9

    authors: Goyal A,Coulson SG,Wu JM,Suvarna SK,Reed MW,Caddy CM

    更新日期:2011-08-01 00:00:00

  • Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature.

    abstract::Angiosarcoma of the breast (AB) is a rare entity: its overall incidence is estimated at between 0.002% and 0.005% per year. Some potential risk factors have been described, mainly previous irradiation of the breast. We report the experience of the European Institute of Oncology with this unusual disease from January 1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9429-z

    authors: Luini A,Gatti G,Diaz J,Botteri E,Oliveira E,Cecilio Sahium de Almeida R,Veronesi P,Intra M,Pagani G,Naninato P,Viale G

    更新日期:2007-09-01 00:00:00

  • Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).

    abstract::Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(6...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-008-9894-7

    authors: Kahán Z,Spanik S,Wagnerova M,Skacel T,Planko B,Fitzthum E,Lindner E,Soldatenkova V,Zielinski CC,Brodowicz T

    更新日期:2008-12-01 00:00:00

  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

    abstract:PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06012-7

    authors: Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

    更新日期:2020-11-18 00:00:00

  • Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

    abstract:PURPOSE:Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4178-8

    authors: Conway K,Edmiston SN,Parrish E,Bryant C,Tse CK,Swift-Scanlan T,McCullough LE,Kuan PF

    更新日期:2017-06-01 00:00:00

  • Tai chi for breast cancer patients: a systematic review.

    abstract::The objective of this review was to assess the effectiveness of tai chi for supportive breast cancer care. Eleven databases were searched from inception through December 2009. Controlled trials testing tai chi in patients with breast cancer that assessed clinical outcome measures were considered. The selection of stud...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0741-2

    authors: Lee MS,Choi TY,Ernst E

    更新日期:2010-04-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract::Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3608-8

    authors: Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期:2015-11-01 00:00:00

  • A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

    abstract::Bone morphogenetic proteins (BMPs) regulate diverse cellular processes, such as proliferation, differentiation, and apoptosis. The BMPs have been studied in several cancers, but thus far contradictory results have been obtained and, especially in breast cancer, information on BMPs is still limited. We performed a syst...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9362-1

    authors: Alarmo EL,Kuukasjärvi T,Karhu R,Kallioniemi A

    更新日期:2007-06-01 00:00:00

  • Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.

    abstract::The aromatase inhibitor 10-propargylestr-4-ene-3,17-dione (PED) has been evaluated in vivo as an anticancer agent. Prolonged administration of PED to rats bearing dimethylbenzanthracene-induced mammary tumors resulted in significant regression of hormone-responsive tumors within several days. Greater than 50% regressi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00682696

    authors: Zimniski SJ,Brandt ME,Covey DF,Puett D

    更新日期:1993-01-01 00:00:00

  • Evaluating breast cancer risk projections for Hispanic women.

    abstract::For Hispanic women, the Breast Cancer Risk Assessment Tool (BCRAT; "Gail Model") combines 1990-1996 breast cancer incidence for Hispanic women with relative risks for breast cancer risk factors from non-Hispanic white (NHW) women. BCRAT risk projections have never been comprehensively evaluated for Hispanic women. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1900-9

    authors: Banegas MP,Gail MH,LaCroix A,Thompson B,Martinez ME,Wactawski-Wende J,John EM,Hubbell FA,Yasmeen S,Katki HA

    更新日期:2012-02-01 00:00:00

  • Clinical significance of angiogenic factors in breast cancer.

    abstract::Growth, progression, and metastasis of breast cancer, as well as of most of the other tumors, are angiogenesis-dependent processes. Several pro-angiogenic growth factors and endogenous inhibitors of angiogenesis have been identified and sequenced, and experimental studies suggest that angiogenic activity of a tumor ma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1006175504673

    authors: Locopo N,Fanelli M,Gasparini G

    更新日期:1998-01-01 00:00:00

  • Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.

    abstract::Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER-) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3861-5

    authors: Hirko KA,Fortner RT,Hankinson SE,Wu T,Eliassen AH

    更新日期:2016-07-01 00:00:00

  • Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women.

    abstract::In previous investigations of adolescent activity recalled in adulthood, modest reductions in risk of benign breast disease (BBD) and premenopausal breast cancer were seen with moderate-strenuous activity during high school. We therefore investigated physical activity, walking, and recreational inactivity (watching TV...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3055-y

    authors: Berkey CS,Tamimi RM,Willett WC,Rosner B,Lindsay Frazier A,Colditz GA

    更新日期:2014-08-01 00:00:00

  • Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.

    abstract::Tamoxifen has been used for the treatment of breast cancer since the 1970s, but is considered a carcinogen because it has been linked to liver cancer in rats and an increased risk of endometrial cancer in patients. In rats, DNA adducts appear to be responsible for carcinogenesis, but their contribution to carcinogenes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006311214152

    authors: Hellmann-Blumberg U,Taras TL,Wurz GT,DeGregorio MW

    更新日期:2000-03-01 00:00:00

  • Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.

    abstract:PURPOSE:Mitochondrial unfolding protein are abundant in breast cancer cells, but the mechanism by which breast cancer cells resist apoptosis is still not fully elucidated. In this study, we explored the role of mitochondrial unfolded protein response (mtUPR)-related proteins in four types of breast cancer tissues. MET...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05729-9

    authors: Chen FM,Huang LJ,Ou-Yang F,Kan JY,Kao LC,Hou MF

    更新日期:2020-08-01 00:00:00

  • Tamoxifen aziridine binding to cytosolic proteins from human breast specimens is negatively associated with estrogen receptors, progesterone receptors, pS2, and cathepsin-D.

    abstract::[3H]Tamoxifen Aziridine ([3H]TAZ) is a derivative of the antiestrogen tamoxifen that covalently labels the Estrogen Receptor (ER), and perhaps other uncharacterized proteins. In a previous article we described that [3H]TAZ binds to a cytosolic protein from human uterine tissues that shares some, but not all, the ER pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006062510883

    authors: Navarro D,Doreste H,Cabrera JJ,Morales M,Díaz-Chico JC,Díaz-Chico BN

    更新日期:1998-07-01 00:00:00

  • Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

    abstract:PURPOSE:Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS:We constructed a Markov model to assess the cost-effectiveness of four diffe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3978-6

    authors: Diaby V,Adunlin G,Ali AA,Zeichner SB,de Lima Lopes G,Kohn CG,Montero AJ

    更新日期:2016-11-01 00:00:00

  • Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

    abstract::Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2671-2

    authors: Heikkinen T,Korpela T,Fagerholm R,Khan S,Aittomäki K,Heikkilä P,Blomqvist C,Carpén O,Nevanlinna H

    更新日期:2013-08-01 00:00:00

  • Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.

    abstract:OBJECTIVES:Improvements in the life expectancy of women with breast cancer raise important questions how to improve quality of life (QoL) for women sustaining complications and side effects of cancer treatment. The presented study examined the prevalence of arm morbidity in a cohort of primary breast cancer patients ov...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9247-3

    authors: Albert US,Koller M,Kopp I,Lorenz W,Schulz KD,Wagner U

    更新日期:2006-12-01 00:00:00